

Patients that used 3M™ Prevena™ Therapy experienced reduced complications and reoperation after breast reconstruction

Clinical evidence (level III): Plastic surgery


Summary of findings

The use of Prevena Therapy following post-mastectomy breast reconstruction was associated with significantly lower rates of infection, dehiscence, necrosis and seromas. A significantly shorter time to drain removal and fewer returns to the OR were also achieved.

In addition to the above observed clinical outcomes,¹ an economic analysis relying on this study data showed a mean per patient cost saving for SSC of \$218.²


\$2,010 Prevena Therapy vs. \$2,228 standard of care

RESULTS




Reduction in SSCs*

8.5% (28/331) Prevena Therapy vs. 15.9% (53/334) SOC (p=0.0092)*




Reduction in SSIs*

2.1% (7/331) Prevena Therapy vs. 4.5% (15/334) SOC (p=0.0225)*




Reduction in seroma*

1.8% (6/331) Prevena Therapy vs. 5.7% (19/334) SOC (p=0.0106)*




Reduction in reoperations*

2.4% (8/331) Prevena Therapy vs. 5.4% (18/334) SOC (p=0.0496)*



Reduction in dehiscence*

2.4% (8/331) Prevena Therapy vs. 5.4% (18/334) SOC (p=0.0178)*



Reduction in necrosis*

5.1% (17/331) Prevena Therapy vs. 9.3% (31/334) SOC (p=0.0070)*

Calculation(s) are derived based on relative patient group incidence rate reported in this study

* Statistically significant (p<0.05)

Study design

Retrospective, comparative study (Level III)

Study purpose

The investigators compared incision management outcomes in patients who received 3M™ Prevena™ Therapy versus standard of care (SOC) after breast reconstruction mastectomy

Methods

- Single site retrospective observational study: 2009–2017
- 356 patients (Prevena Therapy n=177 v SOC n=179)
- 665 closed breast incisions (Prevena Therapy n=331 vs. SOC n=334)
- SOC: 3M™ Steri-Strip™ Wound Closures
- 3M™ Prevena™ Plus Customizable Dressing

- Patients were discharged home after 1 night stay and returned for follow-up on POD 3 and 7.
- Patient demographics, chemotherapy exposure, surgical technique, number of drains, time to drain removal, and 90-day postoperative complication rates were analyzed.

1. Gabriel A, et al. (Loma Linda University). The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes. *Plast Reconstr Surg Glob Open*. 2018;6:e1880.

2. Gabriel A, Maxwell P. Economic analysis based on the use of closed-incision negative-pressure therapy after postoperative breast reconstruction. *Plast Reconstr Surg* 2019;143:36S.

Understanding relevant risk factors for plastic surgery procedures

Patient Risk Stratification

How to identify the patient as high risk for surgical site infection or complication:

Clinical data¹ has shown that a patient should receive Prevena Therapy if they have **one or more** of the following high-risk factors:

- **BMI \geq 30**
- **Smokers**
- **Radiation**
- **Corticosteroids**
- **Revision surgery within 30 days**
- **Extensive undermining**



Scan this QR code to learn more about when to use Prevena Therapy.

1. Gabriel A, et al. (Loma Linda University). The Impact of Closed Incision Negative Pressure Therapy on Postoperative Breast Reconstruction Outcomes. *Plast Reconstr Surg Glob Open*. 2018;6:e1880.

Advancing the Standard of Care.



3M Company
2510 Conway Ave.
St. Paul, MN 55144 USA

Phone 1-800-275-4524 (NPWT products)
1-800-228-3957

Web 3M.com/Medical

3M™ Prevena™ 125 Therapy Unit and 3M™ Prevena™ Plus 125 Therapy Unit manage the environment of closed surgical incisions and remove fluid away from the surgical incision via the application of -125mmHg continuous negative pressure. When used with legally marketed compatible dressings, Prevena 125 and Prevena Plus 125 Therapy Units are intended to aid in reducing the incidence of seroma; and, in patients at high risk for post-operative infections, aid in reducing the incidence of superficial surgical site infection in Class I and Class II wounds.

The effectiveness of Prevena Therapy in reducing the incidence of SSIs and seroma in all surgical procedures and populations has not been demonstrated. See full indications for use and limitations at mykci.com.

NOTE: Specific indications, limitations, contraindications, warnings, precautions and safety information exist for these products and therapies. Please consult a clinician and product instructions for use prior to application. Rx only.

© 2022 3M. All rights reserved. 3M and the other marks shown are marks and/or registered trademarks. Unauthorized use prohibited. US_70-2013-1448-4 (04/22)